BioNTech SE
NASDAQ:BNTX
Gross Margin
BioNTech SE
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | DE |
Market Cap | 22.4B USD |
Gross Margin |
79%
|
Country | US |
Market Cap | 274.3B USD |
Gross Margin |
66%
|
Country | US |
Market Cap | 161B USD |
Gross Margin |
66%
|
Country | US |
Market Cap | 115.4B USD |
Gross Margin |
87%
|
Country | US |
Market Cap | 107.2B USD |
Gross Margin |
86%
|
Country | AU |
Market Cap | 135.6B AUD |
Gross Margin |
52%
|
Country | US |
Market Cap | 79.7B USD |
Gross Margin |
76%
|
Country | US |
Market Cap | 58.7B USD |
Gross Margin |
22%
|
Country | US |
Market Cap | 43.1B USD |
Gross Margin |
75%
|
Country | US |
Market Cap | 31.8B USD |
Gross Margin |
75%
|
Country | KR |
Market Cap | 36.9T KRW |
Gross Margin |
47%
|
Profitability Report
View the profitability report to see the full profitability analysis for BioNTech SE.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on BioNTech SE's most recent financial statements, the company has Gross Margin of 79.4%.